rocuronium bromide


PT Novell


Prosweal Healthcare
Concise Prescribing Info
Rocuronium Br
Adjunct to general anaesth to facilitate tracheal intubation during routine sequence induction & to provide skeletal muscle relaxation during surgery in adults & neonates to adolescents (0 to <18 yr). Adjunct in ICU to facilitate intubation & mechanical ventilation; facilitate tracheal intubation during rapid sequence induction in adults.
Dosage/Direction for Use
Tracheal intubation Standard dose: 0.6 mg/kg. Rapid sequence induction of anaesth 1 mg/kg. Higher doses: 2 mg/kg. Maintenance: 0.15 mg/kg. Reduce dose to 0.075-0.1 mg/kg in long-term inhalational anaesth. Continuous infusion: Loading dose of 0.6 mg/kg. IV anaesth Infusion rate: 0.3-0.6 mg/kg/hr. Inhalational anaesth Infusion rate: 0.3-0.4 mg/kg/hr. Geriatric patient & patient w/ hepatic & biliary tract disease; &/or renal failure 0.6 mg/kg. Maintenance: 0.075-0.1 mg/kg. Infusion rate: 0.3-0.4 mg/kg/hr.
Hypersensitivity to rocuronium Br or to Br ion.
Special Precautions
Mandatory ventilatory support for patients until adequate spontaneous respiration is restored. Extubate only after the patient has recovered sufficiently from neuromuscular block. Cross-sensitivity to neuromuscular blockers. Prolonged paralysis &/or skeletal muscle weakness in long term use. Monitor neuromuscular transmission throughout the use. Myopathy in combination w/ corticosteroid after long term administration. Delay administration until patient is clinically recovered from neuromuscular block induced by suxamethonium. Pregnancy & lactation. Elderly (>65 yr).
Adverse Reactions
Inj site pain/reaction, changes in vital signs & prolonged neuromuscular block. Anaphylactic & anaphylactoid reactions.
Drug Interactions
Potentiated neuromuscular block w/ halogenated volatile anaesth. Prolonged duration of neuromuscular block or myopathy w/ corticosteroids. Recurarisation w/ post-op aminoglycoside, lincosamide, polypeptide & acylamino-penicillins, quinidine, quinine & Mg salts. Decreased effects w/ prior chronic administration of phenytoin or carbamazepine; Ca chloride, K chloride; protease inhibitors (gabexate, ulinastatin). May produce attenuation or potentiation of neuromuscular block w/ non-depolarizing neuromuscular blockers & suxamethonium. May result in quicker onset of action w/ lidocaine. Diuretics, Ca-channel blocking agents, lithium salts, local anaesth, phenytoin or β-blocking agents.
MIMS Class
Neuromuscular Blocking Agents
ATC Classification
M03AC09 - rocuronium bromide ; Belongs to the class of other quaternary ammonium-containing agents used as peripherally-acting muscle relaxants.
Noveron soln for inj 10 mg/mL
6 mL x 12 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in